May 10 (Reuters) - Bluejay Diagnostics Inc BJDX.O :
* BLUEJAY DIAGNOSTICS REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS
* BLUEJAY DIAGNOSTICS INC - CASH AND CASH EQUIVALENTS ON
MARCH 31,
2023 WERE $6.8 MILLION, AS COMPARED TO $10.1 MILLION ON DECEMBER
31, 2022
* BLUEJAY DIAGNOSTICS INC - WILL LIMIT ITS CASH BURN DURING
FDA
SUBMISSION PROCESS AND CONTINUE TO CLOSELY MONITOR MANAGEMENT OF
ITS LIQUIDITY
* BLUEJAY DIAGNOSTICS INC - QTRLY LOSS PER SHARE $0.12
* BLUEJAY DIAGNOSTICS INC - LOOK FORWARD TO PROVIDING AN
UPDATE ON
OUR SYMPHONY IL-6 CLINICAL PROGRAM DURING THIS QUARTER
Source text for Eikon: ID:nGNX4HxqyG
Further company coverage: BJDX.O
((Reuters.Briefs@thomsonreuters.com;))